Trial Profile

A Phase 1 clinical trial of OLX75016

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OLX 702A (Primary)
Indications Non-alcoholic steatohepatitis
Focus Adverse reactions
Sponsors OliX Pharmaceuticals

Most Recent Events

10 Feb 2025 According to an OliX Pharmaceuticals media release, the company announced that it will receive an initial payment from Lilly to complete the Phase 1 clinical trial, currently underway in Australia.
13 Feb 2024 According to an OliX Pharmaceuticals media release, first patient had been dosed in this trial, The phase 1 trial is ongoing in Brisbane, Australia
13 Feb 2024 Status changed from not yet recruiting to recruiting as per OliX Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com